Your browser doesn't support javascript.
loading
Neurocognitive and clinical profile of male patients with substance use disorder in early remission phase with and without comorbid depression.
Marquez-Arrico, Julia E; Catalán-Aguilar, Judit; Navarro, José Francisco; Adan, Ana.
Afiliación
  • Marquez-Arrico JE; Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain; Institute of Neurosciences, University of Barcelona, 08035 Barcelona, Spain.
  • Catalán-Aguilar J; Department of Psychobiology, Psychology Center, Universitat de València, Av. Blasco Ibáñez, 21, 46010 Valencia, Spain; Institut d'Investigació en Psicologia dels Recursos Humans, del Desenvolupament Organitzacional i de la Qualitat de Vida Laboral (Idocal), Universitat de València, Av. Blasco Ibáñez
  • Navarro JF; Department of Psychobiology, School of Psychology, University of Málaga, Campus de Teatinos s/n, 29071 Málaga, Spain.
  • Adan A; Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain; Institute of Neurosciences, University of Barcelona, 08035 Barcelona, Spain. Electronic address: aadan@ub.edu.
Article en En | MEDLINE | ID: mdl-39002929
ABSTRACT
Substance Use Disorder (SUD) represents one of the most frequent conditions worldwide which commonly coexists with major depressive disorder (MDD). This comorbidity (SUD + MDD) is one of the most prevalent with patients showing certain social and clinical characteristics that could lead to a worsening of their cognitive performance. However, despite these particularities, only a few studies have addressed the possible differences in cognitive performance between patients with SUD + MDD compared with those with SUD-only patients. Therefore, the aim of this study is to examine the clinical and cognitive profile of patients with SUD + MDD vs. SUD-only who are in early remission phase. For this purpose, 271 male patients underwent a clinical and neuropsychological assessment (SUD + MDD group N = 101; SUD-only group N = 170). Results indicated that SUD + MDD patients showed worse cognitive performance than SUD in visuospatial reasoning, verbal memory and learning, recognition, and processing speed even after a 3-month period of abstinence. Furthermore, these patients exhibited more self-reported prefrontal symptoms, as well as worse social and clinical conditions. This study indicates that the neurocognitive and clinical profile of patients with SUD + MDD could represent a risk since their characteristics have been associated with poorer recovery and prognosis. Our results could be helpful in clinical practice highlighting the need for cognitive remediation strategies in these populations, providing information that would allow the implementation of more appropriate treatments and preventive strategies.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Prog Neuropsychopharmacol Biol Psychiatry Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Prog Neuropsychopharmacol Biol Psychiatry Año: 2024 Tipo del documento: Article País de afiliación: España